Lorazepam
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Lorazepam: From Anxiety and Sedation to Trigeminal Nerve Neoplasm
One-Sentence Summary
Lorazepam is a benzodiazepine (BZD) widely used for short-term management of anxiety, insomnia, and acute seizure control, acting through GABA-A receptor enhancement to suppress central nervous system excitability. The TxGNN model predicts it may be relevant for Trigeminal Nerve Neoplasm with a score of 99.87%, yet there are currently no clinical trials and no publications directly supporting this indication. This high model score most likely reflects an indirect knowledge graph pathway rather than a direct antitumor mechanism, making the evidence base insufficient to advance without further investigation.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Anxiety disorders, insomnia, and acute seizure management (established BZD indications; no Singapore regulatory record available) |
| Predicted New Indication | Trigeminal Nerve Neoplasm |
| TxGNN Prediction Score | 99.87% |
| Evidence Level | L5 |
| Singapore Market Status | Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on known pharmacology, Lorazepam is a short-to-intermediate-acting benzodiazepine that acts as a positive allosteric modulator at the GABA-A receptor, enhancing chloride influx and suppressing neuronal excitability. This produces its well-established anxiolytic, sedative, anticonvulsant, and muscle-relaxant effects. It is a first-line agent for status epilepticus and a recognised short-term treatment for anxiety-related insomnia.
Trigeminal nerve neoplasms are rare tumours arising from the fifth cranial nerve and its branches — most commonly schwannomas, but also meningiomas and malignant peripheral nerve sheath tumours. These lesions frequently produce severe neuropathic facial pain, paresthesias, and sensory loss; secondary anxiety and sleep disruption are common in affected patients. There is no established pharmacological rationale for GABA-A modulation influencing tumour growth or regression in this tissue type.
The TxGNN model's high score for this pairing most likely reflects an indirect knowledge graph pathway of the form: trigeminal nerve neoplasm → neuropathic pain / secondary anxiety → benzodiazepine therapy. This is a symptom-level association, not a direct antitumour mechanism. Without any supporting clinical trial or published literature, this prediction should be treated as a hypothesis-generating signal only and does not provide sufficient basis for a repurposing programme.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
Lorazepam is currently not marketed in Singapore. No product registrations are on record in the HSA database.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN prediction for trigeminal nerve neoplasm rests on an indirect, symptom-mediated knowledge graph association with zero supporting clinical trials or published literature (Evidence Level L5). There is no mechanistic case for Lorazepam acting on tumour biology in this indication, and Singapore regulatory data for this drug is entirely absent.
To proceed, the following is needed:
- Detailed MOA data confirming whether GABA-A modulation has any direct antitumour or neuroprotective effect in trigeminal nerve neoplasm biology
- Preclinical studies (in vitro cell-line or animal model) evaluating the effect of benzodiazepines on trigeminal schwannoma or meningioma growth
- Full safety profile and contraindication data from the Singapore package insert or equivalent regional label
- Clarity on the therapeutic intent: if the goal is symptom management (e.g., anxiety or sleep disruption secondary to trigeminal nerve neoplasm) rather than direct antitumour activity, a repositioning strategy focused on supportive/palliative use should be evaluated separately under a different clinical framework
- Re-evaluation of whether the rank-2 indication (Insomnia, Evidence Level L2) represents a more actionable near-term repurposing opportunity for this drug in the Singapore market
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.